<i>Ercc1</i> Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a <i>Tp53</i> Context-Specific Manner

Abstract

This study provides a solid rationale for the stratification of lung adenocarcinoma patients according to the functional ERCC1- and mutational TP53 status, where functionally ERCC1-incompetent patients could benefit from sequential cisplatin and etoposide chemotherapy. Mol Cancer Res; 14(11); 1110-23. ©2016 AACR.